Literature DB >> 24419122

Assessing progress in reducing the burden of cancer mortality, 1985-2005.

Samir Soneji1, Hiram Beltrán-Sánchez, Harold C Sox.   

Abstract

PURPOSE: Measuring the effect of cancer interventions must take into account rising cancer incidence now that people live longer because of declines in mortality from cardiovascular disease (CVD). Cancer mortality rates in the population do not accomplish this objective. We sought a measure that would reveal the effects of changing mortality rates from other diseases.
METHODS: We obtained annual breast, colorectal, lung, and prostate cancer mortality rates from the Surveillance, Epidemiology, and End Results registries; we obtained noncancer mortality rates from national death certificates, 1975 to 2005. We used life-table methods to calculate the burden of cancer mortality as the average person-years of life lost (PYLL) as a result of cancer (cancer-specific PYLL) and quantify individual-and perhaps offsetting-contributions of the two factors that affect cancer-specific PYLL: mortality rates as a result of cancer and other-cause mortality.
RESULTS: Falling cancer mortality rates reduced the burden of mortality from leading cancers, but increasing cancer incidence as a result of decreasing other-cause mortality rates partially offset this progress. Between 1985 and 1989 and between 2000 and 2004, the burden of lung cancer in males declined by 0.1 year of life lost. This decline reflects the sum of two effects: decreasing lung cancer mortality rates that reduced the average burden of lung cancer mortality by 0.33 years of life lost and declining other-cause mortality rates that raised it by 0.23 years. Other common cancers showed similar patterns.
CONCLUSION: By using a measure that accounts for increased cancer incidence as a result of improvements in CVD mortality, we find that prior assessments have underestimated the impact of cancer interventions.

Entities:  

Mesh:

Year:  2014        PMID: 24419122      PMCID: PMC3912329          DOI: 10.1200/JCO.2013.50.8952

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  22 in total

1.  A method for constructing complete annual U.S. life tables.

Authors:  R N Anderson
Journal:  Vital Health Stat 2       Date:  2000

2.  Progress against cancer (1971-2011): how far have we come?

Authors:  A K Tiwari; H K Roy
Journal:  J Intern Med       Date:  2011-10-20       Impact factor: 8.989

3.  Progress in the war on cancer.

Authors:  Susan M Gapstur; Michael J Thun
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

4.  Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.

Authors:  Matthew J Hayat; Nadia Howlader; Marsha E Reichman; Brenda K Edwards
Journal:  Oncologist       Date:  2007-01

5.  Are we finally winning the war on cancer?

Authors:  David M Cutler
Journal:  J Econ Perspect       Date:  2008

6.  Cancer crusade at 40. Celebrating an anniversary. Introduction.

Authors:  Paula Kiberstis; Eliot Marshall
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

7.  An integrated approach to cause-of-death analysis: cause-deleted life tables and decompositions of life expectancy.

Authors:  Hiram Beltrán-Sánchez; Samuel H Preston; Vladimir Canudas-Romo
Journal:  Demogr Res       Date:  2008-07-01

8.  Declining death rates reflect progress against cancer.

Authors:  Ahmedin Jemal; Elizabeth Ward; Michael Thun
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

9.  Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States.

Authors:  Ahmet Ergin; Paul Muntner; Roger Sherwin; Jiang He
Journal:  Am J Med       Date:  2004-08-15       Impact factor: 4.965

10.  A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer.

Authors:  K C Chu; B A Miller; E J Feuer; B F Hankey
Journal:  J Clin Epidemiol       Date:  1994-12       Impact factor: 6.437

View more
  9 in total

1.  Equity and length of lifespan are not the same.

Authors:  Benjamin Seligman; Gabi Greenberg; Shripad Tuljapurkar
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-11       Impact factor: 11.205

2.  Emerging Regional and Racial Disparities in the Lifetime Risk of Human Immunodeficiency Virus Infection Among Men who Have Sex With Men: A Comparative Life Table Analysis in King County, WA and Mississippi.

Authors:  Galant A Chan; Kendra L Johnson; Nicholas G Mosca; Thomas E Dobbs; Julia C Dombrowski; Amy B Bennett; Susan E Buskin; Matthew R Golden
Journal:  Sex Transm Dis       Date:  2017-04       Impact factor: 2.830

3.  Use of the Prostate Core Mitomic Test in Repeated Biopsy Decision-Making: Real-World Assessment of Clinical Utility in a Multicenter Patient Population.

Authors:  Lorena Legisi; Elise DeSa; M Nasar Qureshi
Journal:  Am Health Drug Benefits       Date:  2016-12

4.  Potential for improvement in cancer management: reducing mortality in the European Union.

Authors:  Carlo La Vecchia; Matteo Rota; Matteo Malvezzi; Eva Negri
Journal:  Oncologist       Date:  2015-04-17

5.  Development of a nomogram for preoperative prediction of lymph node metastasis in non-small cell lung cancer: a SEER-based study.

Authors:  Chufan Zhang; Qian Song; Lanlin Zhang; Xianghua Wu
Journal:  J Thorac Dis       Date:  2020-07       Impact factor: 2.895

6.  Years of life lost as a measure of cancer burden on a national level.

Authors:  O T Brustugun; B Møller; A Helland
Journal:  Br J Cancer       Date:  2014-07-01       Impact factor: 7.640

7.  Benchmarking life expectancy and cancer mortality: global comparison with cardiovascular disease 1981-2010.

Authors:  Bochen Cao; Freddie Bray; Hiram Beltrán-Sánchez; Ophira Ginsburg; Samir Soneji; Isabelle Soerjomataram
Journal:  BMJ       Date:  2017-06-21

8.  Lung cancer mortality and years of potential life lost among males and females over six decades in a country with high smoking prevalence: an observational study.

Authors:  Ulrich John; Monika Hanke
Journal:  BMC Cancer       Date:  2015-11-09       Impact factor: 4.430

Review 9.  Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.

Authors:  Luca Falzone; Salvatore Salomone; Massimo Libra
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.